Filtered By:
Drug: Temodar
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 1478 results found since Jan 2013.
EZH2-regulated PARP 1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide
CONCLUSION: EZH2 PARP 1 signaling axis is possibly responsible for the chemoresistance of gliomas to TMZ. Simultaneously inhibiting these two genes may improve the outcome of TMZ chemotherapy.PMID:37594167 | DOI:10.2174/1568009623666230818151830
Source: Current Cancer Drug Targets - August 18, 2023 Category: Cancer & Oncology Authors: Qiang Liang Bing Wang Chenran Zhang Chaoli Song Junyu Wang Wei Sun Lei Jiang Jing Lin Source Type: research
Invadopodia associated Thrombospondin-1 contributes to a post-therapy pro-invasive response in glioblastoma cells
In this study we utilized a Nanostring® Cancer Progression gene expression panel to identify candidate genes that may be involved in enhanced GBM cell invasion after treatment with clinically relevant doses of RT/TMZ. Our findings identified thrombospondin-1 (THBS1) as a pro-invasive gene that is upregulated in these cells. Immunofluorescence staining revealed that THBS1 localised within functional matrix-degrading invadopodia that formed on the surface of GBM cells. Furthermore, overexpression of THBS1 resulted in enhanced GBM cell migration and secretion of MMP-2, which was reduced with silencing of THBS1. The prelimina...
Source: Experimental Cell Research - August 17, 2023 Category: Cytology Authors: Clarissa A Whitehead Andrew P Morokoff Andrew H Kaye Katharine J Drummond Theo Mantamadiotis Stanley S Stylli Source Type: research
A pilot phase Ib study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wild-type glioblastoma
CONCLUSIONS: Concurrent tadalafil is well tolerated during chemoradiotherapy for GBM. Tadalafil is associated with a reduction of peripheral MDSCs after chemoradiotherapy and increased CD8 T-cell proliferation and activation.PMID:37554225 | PMC:PMC10406429 | DOI:10.1093/noajnl/vdad088
Source: Cancer Control - August 9, 2023 Category: Cancer & Oncology Authors: Subhajit Ghosh Tanner M Johanns Milan G Chheda Eric Liu Omar Butt Christopher Abraham Shahed Badiyan Yi Huang David DeNardo Albert H Kim Dennis Hallahan Dinesh Thotala Jiayi Huang Source Type: research
Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression
CONCLUSIONS: High NLR is associated with worse outcomes in newly diagnosed and recurrent glioblastoma. Appropriate eligibility criteria and accounting and reporting of blood-based biomarkers are important in the design and interpretation of newly diagnosed and recurrent glioblastoma trials.PMID:37554224 | PMC:PMC10406420 | DOI:10.1093/noajnl/vdad083
Source: Adv Data - August 9, 2023 Category: Epidemiology Authors: Davy Deng Lubna Hammoudeh Gilbert Youssef Yu-Hui Chen Kee-Young Shin Mary Jane Lim-Fat Jose Ricardo McFaline-Figueroa Ugonma N Chukwueke Shyam Tanguturi David A Reardon Eudocia Q Lee Lakshmi Nayak Wenya Linda Bi Omar Arnaout Keith L Ligon Patrick Y Wen Ri Source Type: research
Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas
CONCLUSIONS: Combination of PAC-1 and TMZ was well tolerated up to 625 mg orally daily and TMZ orally 150 mg/m2/5 days per 28-day cycle. The maximum tolerated dose was not reached. Further dose escalation of PAC-1 in combination with TMZ is advised before conducting a formal prospective efficacy study in this patient population.PMID:37554223 | PMC:PMC10406430 | DOI:10.1093/noajnl/vdad087
Source: Adv Data - August 9, 2023 Category: Epidemiology Authors: Matthias Holdhoff M Kelly Nicholas Richard A Peterson Stefania Maraka Li C Liu James H Fischer Jeffrey S Wefel Timothy M Fan Tracy Vannorsdall Meredith Russell Michaella Iacoboni Theodore M Tarasow Paul J Hergenrother Arkadiusz Z Dudek Oana C Danciu Source Type: research
